17 trends tracked about this subject — the full history, oldest to newest below.
Rising concerns over GLP-1 weight-loss drug overdoses are linked to dosing errors and the use of telehealth services.
Medical discussions are intensifying over whether GLP-1 medications like Ozempic can prevent cancer or influence oncology recovery.
A new oral GLP-1 weight-loss pill is showing results that outperform oral Ozempic in major clinical trials.
Doctors are warning GLP-1 medication users about 'Ozempic feet,' a surprising side effect emerging as weight-loss drugs grow in popularity.
Public scrutiny regarding the mental, physical, and legal implications of GLP-1 receptor agonists intensifies amid reports of potential litigation.
Employers and public health programs are limiting access to GLP-1 obesity drugs due to rising costs and budget constraints.
The rise of GLP-1 medications like Ozempic is creating a new surge in demand for plastic surgery and aesthetic medicine to treat skin side effects.
Public discourse and clinical research are shifting toward the long-term psychological and addictive-behavior impacts of GLP-1 medications.
An unapproved weight-loss drug is gaining attention for its powerful effects and potential health risks.
Researchers and doctors are exploring the broader implications of GLP-1 weight loss drugs as their use becomes more widespread.
New research indicates that GLP-1 receptor agonists, including Ozempic, are being misused by individuals with eating disorders.
Ozempic users report unexpected changes in their sense of smell and taste.
Medical professionals are debunking a viral social media trend promoting gelatin drinks as a 'natural Ozempic' for weight loss.
Research suggests weight-loss drugs like Ozempic may also help treat addiction.
Medical experts are warning patients taking specific antidepressants and other medications about health risks and reduced efficacy during summer heat.
New study data suggests GLP-1 medications like Ozempic and Wegovy may reduce fracture risks and improve bone health in Type 2 diabetes patients.
New research indicates a trend of decreased physical activity among individuals using GLP-1 weight loss medications like Ozempic and Wegovy.